Credo Technology Group Holding Ltd vs Zoetis Inc — how do they compare? Credo Technology Group Holding Ltd trades at $216.55 (market cap $39.82B), while Zoetis Inc trades at $74.77 (market cap $30.20B). The key difference: Credo Technology Group Holding Ltd is the larger of the two by market cap, and Zoetis Inc pays a 2.9% dividend while Credo Technology Group Holding Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold Credo Technology Group Holding Ltd for 22 Days and Zoetis Inc for 70 Days on average.
| CRDO | ZTS | |
|---|---|---|
Market Cap | $39.82B | $30.20B |
Volume | 9,451,558 | 6,175,327 |
Sector | Technology | Health |
52-Week High | $302.52 | $147.53 |
52-Week Low | $87.81 | $69.09 |
Typical Hold Time | 22 Days | 70 Days |
Enterprise Value | $39.08B | $37.76B |
Dividend Yield | — | 2.9% |
Signals from Pluang's Aura AI — not financial advice
CRDO trades at $211.86, down 3.7% on the day but maintains strong technical momentum with bullish moving averages and key support at $204. The company demonstrates exceptional growth with 114.7% YoY revenue expansion and 33.83% net margins, though valuation multiples remain elevated at P/E of 74.6. Recent earnings beats and analyst consensus of $267.33 price target suggest continued upside potential despite insider selling activity.
Outlook remains positive driven by AI infrastructure demand and optical technology expansion, with management targeting 85%+ revenue growth. Key risks include premium valuation, customer concentration, and execution challenges as the company scales. The stock offers growth exposure to high-speed connectivity solutions but requires monitoring of margin trends and competitive dynamics.
Zoetis (ZTS) trades at $73.08, up 2.14% today, with a bullish technical signal but mixed earnings history including a recent Q1 2026 miss. The stock shows strong profitability with a 27.69% net income margin and 64.91% ROE, while valuation metrics like a P/E of 11.92 appear reasonable. Recent news highlights competitive pressures in the U.S. pet care market, though international segments remain resilient.
The outlook is cautiously optimistic; ZTS faces near-term headwinds from weak U.S. demand and competition, but its industry-leading margins and dominant market position support long-term growth. Risks include pricing erosion and guidance cuts, yet the consensus price target of $87.33 suggests upside potential for patient investors.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Credo Technology provides high-speed connectivity solutions for AI-driven applications and hyperscale data centers. Its products enable faster, more energy-efficient data transmission for cloud and telecom infrastructure.
Read more on CRDO →Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →